LTX-315 Peptide Membrane Disruption Selectivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anti-tumor peptides face challenges in achieving selective cytotoxicity towards cancer cells while minimizing harm to normal cells, due to similarities in cell membrane properties between tumor and non-transformed cells, and existing therapies are inadequate in addressing the prevalence of cancer.
Innovation Solution
Development of specific peptides, such as LTX-315, comprising 9 amino acids with 5 cationic and 4 lipophilic residues, including non-genetically coded amino acids, designed to disrupt tumor cell membranes with minimal impact on normal cells, offering both anti-tumor activity and potential as vaccine adjuvants.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If peptides are designed to interact with cell membranes to achieve anti-tumour activity, then cytotoxicity against tumour cells is improved, but selectivity between tumour and normal cells deteriorates due to similar membrane properties
Solution Approach 1:
The peptide incorporates a non-genetically coded amino acid with a specific lipophilic R group that creates local hydrophobic interactions with the membrane. This localized structural feature enables preferential binding to tumour cell membranes while maintaining overall peptide structure, resolving the contradiction between cytotoxicity and selectivity
Solution Approach 2:
The invention modifies the peptide's chemical parameters by incorporating non-genetically coded amino acids with specific lipophilic properties. This changes the peptide's interaction characteristics with cell membranes, enabling enhanced tumour cell selectivity while maintaining anti-tumour activity
2Reliability
If peptides are designed with larger size to achieve good target cell cytotoxicity, then anti-tumour activity is improved, but peptide complexity and difficulty of administration increase
Solution Approach 1:
The invention uses a simplified 9-amino acid sequence that copies the essential functional features of larger anti-tumour peptides. By retaining only the critical cationic and lipophilic residues in a compact arrangement, the peptide achieves effective cytotoxicity without the complexity of larger structures
Solution Approach 2:
The invention extracts and isolates the essential functional elements (5 cationic amino acids and 4 lipophilic amino acids) from larger peptide structures. This extraction creates a minimal effective peptide that maintains cytotoxicity while reducing overall size and complexity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
LTX-315 demonstrates potent cytotoxicity against a range of cancer types with reduced effect on normal cells, showing promise in treating various cancers, including multidrug-resistant forms, and inducing immune responses for long-term protection.
Implementation Method 1
these molecules which exhibit particularly good activity against a range of cancer types and good selectivity for cancerous cells over normal cells... exert a direct membrane-affecting mechanism... destabilising the membrane
Implementation Method 2
Some peptides categorised as class L (lytic) peptides are believed to interact with bacterial cell membranes, forming ion-channels, pores or other structures capable of destabilising the membrane... having amphiphilic character and a net positive charge
Data Source
Figure 1
Figure 2~3
Figure 4~5
AI summary
The present invention relates to peptides or peptide like molecules and their uses in therapy, in particular as anti-tumour agents.